Form 4: OnKure Therapeutics Director Isaac Manke Acquires Shares in Lieu of Cash Retainer

Director Isaac Manke acquired 3,469 shares of OnKure Therapeutics Class A Common Stock in lieu of a quarterly cash retainer.

Summary

• Isaac Manke, a director of OnKure Therapeutics, acquired 3,469 shares of Class A Common Stock on March 31, 2025.
• The acquisition was made in lieu of a quarterly cash retainer under the Issuer's Outside Director Compensation Policy.
• The shares were acquired as fully vested restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, and the director taking equity instead of cash could be seen as a slightly positive sign.

Positives

• A director's decision to take equity instead of cash may signal confidence in the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Directors often receive equity compensation as part of their overall remuneration.

Key Dates

Keywords

OnKure Therapeutics, Director, Isaac Manke, Class A Common Stock, Restricted Stock Units, RSUs, Acquisition, Form 4, Insider Trading